YARD-FORCE
31.1.2024 02:51:31 CET | Business Wire | Press release
Yard Force takes a bold step forward with the introduction of the REVOLA robot lawn mower, challenging the norm in the Outdoor Power Equipment (OPE) market, with fully-featured and Virtual Boundary Technology. Recent data from Statista reveals that the OPE market reached a staggering $33.56 billion in 2022, with an anticipated Compound Annual Growth Rate (CAGR) of 5.6% from 2022 to 2027, projecting a market size of $44.07 billion. Lawn mowers, especially those integrating lithium-ion technology, are at the forefront of this growth, boasting an estimated CAGR of 9%, outpacing other OPE categories.
The REVOLA robot lawn mower from Yard Force emerges as a game-changer, not just as an efficient grass-cutting tool but as a solution to longstanding challenges in the industry. Packed with advanced technologies, the REVOLA promises users a unique and efficient lawn-mowing experience.
Key Features of the REVOLA Robot Lawn Mower:
1. Virtual Boundary Navigation System: The Virtual Boundary Navigation System in the REVOLA is called APNT (Advanced Positioning and Navigation Technology) leverages a multi-faceted approach to ensure accurate and reliable navigation. It utilizes satellite positioning for global location awareness, path planning algorithms for efficient route optimization, ultrasonic sensor for proximity sensing, and VSLAM (Visual Simultaneous Localization and Mapping) technology for real-time visual mapping and positioning. The VSLAM technology is a standout feature, allowing the REVOLA to create a dynamic map of its surroundings, navigate with precision, and adapt to changes in the environment. This technology plays a crucial role in overcoming obstacles, providing flexibility, and ensuring a robust navigation experience even in challenging conditions.
2. Addressing Existing Pain Points: The REVOLA addresses common challenges faced by traditional virtual boundary robot mowers. Unlike its counterparts, the REVOLA's VSLAM technology enables it to accurately cutting even though satellite signal is weak. Additionally, positioning inaccuracies caused by obstacles such as trees, houses, or electric poles are mitigated through the advanced VSLAM technology. This results in a seamless and trouble-free mowing experience for users, eliminating the frustrations associated with traditional navigation limitations.
3. Enhanced Safety Features: Safety is a top priority for the REVOLA, as validated by TÜV Rheinland tests. Traditional satellite-based mowers may face challenges with larger stones, potentially causing damage to blades or posing risks to objects like water pipes and toys. The REVOLA mitigates these risks through its intelligent obstacle recognition and detection system by integrated ultrasonic sensor and RGB camera. This system ensures that the mower can identify obstacles, including stones larger than 10 cm, and take appropriate actions to navigate around them, promoting a safe mowing process and protecting both the mower and the surrounding environment.
4. Optimized Battery Consumption Performance: The REVOLA is designed for efficient and long-lasting performance with its optimized battery consumption thanks to the systematic cut algorithm. Equipped with a powerful 28V 5.7Ah battery, the high-efficiency brushless motor further enhances efficiency, operating at optimal speeds of revolutions per minute (RPM) to ensure precise grass cutting. This combination of a high-capacity battery and a high- efficiency brushless motor contributes to the REVOLA's effectiveness in maintaining lawns while maximizing battery life.
5. Smart Connectivity: Smart Connectivity is a key aspect of the REVOLA, providing users with remote control and monitoring capabilities. The mower is equipped with Bluetooth, 4G, and Wi-Fi connectivity, ensuring comprehensive network coverage. Users can leverage the dedicated app to monitor the mower's progress from anywhere, allowing for real-time tracking of mowing activities. This connectivity not only enhances user convenience but also allows for more personalized and efficient lawn care based on specific preferences and needs.
6. RGB Recognition: RGB recognition in the REVOLA involves the use of Red, Green, and Blue color channels to identify and differentiate various elements within the lawn. The mower employs a sophisticated camera that captures images of the lawn. By analyzing the color spectrum and structure of the grass, the REVOLA can distinguish between different types of vegetation, ensuring a more targeted and efficient mowing process. This feature allows the mower to adapt its mowing pattern based on the specific characteristics of the lawn, resulting in a more precise and customized cutting experience.
7. OTA (Over the Air) Updates: The OTA update capability of the REVOLA enables the mower to receive software updates and enhancements remotely, without requiring manual intervention. This feature ensures that the REVOLA remains current with the latest technological developments, performance optimizations, and bug fixes. Manufacturers can regularly release updates to improve the mower's functionality, address any identified issues, or introduce new features. Users can conveniently download and install these updates over the air, ensuring that their REVOLA mower continues to operate at its best without the need for physical updates or visits to a service center.
Future Outlook and Industry Impact:
As the OPE market continues to evolve, the REVOLA robot lawn mower positions itself as a revolutionary product. Its advanced VSLAM technology, coupled with a user-friendly design, addresses longstanding industry challenges and paves the way for the future of intelligent lawn management. Yard Force's commitment to innovation and excellence sets the REVOLA apart, making it a frontrunner in reshaping the landscape of outdoor power equipment.
About Yard Force:
Yard Force is a world recognized brand dedicated to providing innovative outdoor power equipment solutions. With a focus on cutting-edge technology and user-friendly designs, Yard Force aims to transform the lawn care experience for users worldwide.
Follow Yard Force:
- Website: https://www.yardforce.eu
- Facebook: https://www.facebook.com/YardForceEurope
*Note: The information provided in this press release is based on data available as of Jan 23rd, 2024. Any future developments or changes may not be reflected in this release. *
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240130520868/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom